Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Nature Communications 2026 Open access

Read full text
Authors: Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Silvia Stacchiotti, George D. Demetri, Gregory M. Coté, Mark Agulnik, Rashmi Chugh, Thierry Jahan, Abha A. Gupta, Tom Wei‐Wu Chen, Ravin Ratan
+6 more Palma Dileo, Alexander D. Drilon, Gabriel G. Malouf, Attila Szántó, Neal Gupta, Nizar M. Tannir
DOI: 10.1038/s41467-026-69708-2
Cited by: 3
References: 40

Abstract

Advanced tumors harboring SWI/SNF mutations are rare and aggressive. Often presenting in young patients, treatment options are limited. This phase II basket study (NCT02601950) assessed oral tazemetostat, an EZH2 inhibitor, at 800 mg twice daily (N = 129). Cohorts included malignant rhabdoid tumors (n = 32, Cohort 1), synovial sarcoma (n = 33, Cohort 2), INI1-negative tumors (n = 32, Cohort 3), renal medullary carcinoma (n = 14, Cohort 4), and poorly differentiated chordoma (n = 18, Cohort 7). Efficacy assessments used a 2-stage Green-Dahlberg design. Stage 1 futility was predefined as objective responses (complete/partial [CR/PR])

Fields of Study & Subjects

Chromatin Remodeling and Cancer Neurofibromatosis and Schwannoma Cases Mechanisms of cancer metastasis

Publication details

Journal / source
Nature Communications
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Publication date
25 March 2026
Language
EN